Imricor Wins Landmark FDA Clearance for MRI-Native NorthStar Mapping System

Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:IMR) ) has shared an announcement.

Imricor Medical Systems has secured U.S. FDA 510(k) clearance for its NorthStar Mapping System, the first and only MRI-native 3D mapping and guidance platform to receive such approval, marking its first capital equipment and software-centric product cleared in the U.S. market. The clearance allows commercial launch of NorthStar in the world’s largest electrophysiology market and positions the system as the foundational software hub for interventional cardiac MRI labs, underpinning Imricor’s full MRI-guided electrophysiology platform and opening a new, AI-enabled software era for the company with substantial implications for future product expansion and market growth.

The most recent analyst rating on (AU:IMR) stock is a Hold with a A$2.00 price target. To see the full list of analyst forecasts on Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:IMR Stock Forecast page.

More about Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh

Imricor Medical Systems, Inc. is a medical technology company focused on MRI-guided interventional cardiology, developing uniquely MRI-compatible devices and systems that enable electrophysiology and other minimally invasive cardiac procedures in a radiation-free MRI environment. Its portfolio spans both consumable products and capital equipment, targeting the fast-growing market for interventional cardiac MRI (iCMR) in major electrophysiology markets such as the United States.

Average Trading Volume: 212,255

Technical Sentiment Signal: Buy

Current Market Cap: A$640.9M

For an in-depth examination of IMR stock, go to TipRanks’ Overview page.